A New Series of Antileukemic Agents: Design, Synthesis, In Vitro and In Silico Evaluation of Thiazole-Based ABL1 Kinase Inhibitors

Zeytun, Ebru; ALTINTOP, MEHLİKA; SEVER, BELGİN; ÖZDEMİR, AHMET; Ellakwa, Doha; Ocak, Zeynep; Ciftci, Halil; Otsuka, Masami; Fujita, Mikako; Radwan, Mohamed

doi:10.2174/1871520620666200824100408

A New Series of Antileukemic Agents: Design, Synthesis, In Vitro and In Silico Evaluation of Thiazole-Based ABL1 Kinase Inhibitors

Zeytun E., ALTINTOP M. D., SEVER B., ÖZDEMİR A., Ellakwa D. E., Ocak Z., ...Daha Fazla

ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, cilt.21, sa.9, ss.1099-1109, 2021 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 21 Sayı: 9
Basım Tarihi: 2021
Doi Numarası: 10.2174/1871520620666200824100408
Dergi Adı: ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Biotechnology Research Abstracts, Chemical Abstracts Core, EMBASE, MEDLINE
Sayfa Sayıları: ss.1099-1109
Anahtar Kelimeler: Thiazole, ABL1 kinase, apoptosis, chronic myeloid leukemia, molecular docking, antileukemic agents
Anadolu Üniversitesi Adresli: Evet

Özet

Background: After the approval of imatinib, more than 25 antitumor agents targeting kinases have been approved, and several promising candidates are at various stages of clinical evaluation.